PofoliaShared via Pofolia

Journal of the American College of Surgeons· 2026Q1

Real-World Use and Outcomes of Post-Discharge Venous Thromboembolism Prophylaxis After Thoracic Cancer Operation

Elio R. Bitar, Andrew Hawkins, Kaelyn C. Cummins, Olivia Sears et al.

Short summary

Post-discharge venous thromboembolism prophylaxis after thoracic cancer surgery is associated with reduced DVT, PE, and mortality after esophagectomy, but findings are less consistent after lung resection, with increased bleeding and healthcare use in some cases.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Post-discharge prophylaxis was given to 11.15% of esophagectomy patients and 1.48% of lung resection patients.
  • After esophagectomy (open or minimally invasive), prophylaxis was associated with lower DVT, PE, and mortality.
  • After open lung resection, prophylaxis was linked to lower PE and mortality but higher bleeding and healthcare use.
  • After minimally invasive lung resection, prophylaxis did not significantly improve thromboembolic outcomes and increased bleeding/healthcare use.
  • Enoxaparin was the most common prophylaxis (79.35%), with no significant difference in outcomes between enoxaparin and apixaban.

AI-generated from the title and abstract; the full text is not read.

Abstract

Background: Post-discharge venous thromboembolism prophylaxis is conditionally recommended after thoracic cancer operation, but real-world use and associated outcomes across procedures and operative approaches remain poorly characterized. Study Design: We conducted a retrospective Epic Cosmos cohort study of adults undergoing lung or esophageal cancer resection from 2016-2025. Post-discharge prophylaxis was defined as prophylactic-dose anticoagulation prescribed within 7 days of discharge. Thirty-day outcomes were compared using 1:3 propensity-score matching stratified by procedure and operative approach. Results: Among 157,619 patients (14,277 esophagectomy; 143,342 lung resection), 11.15% and 1.48%, respectively, received post-discharge prophylaxis. After open esophagectomy, prophylaxis was associated with lower DVT (1.23% vs 2.63%; p=0.039), PE (0.46% vs 1.44%; p=0.047), and mortality (1.70% vs 5.20%; p<0.001), without significantly increased bleeding. Findings were similar after minimally invasive esophagectomy: DVT 0.32% vs 1.46% (p=0.003), PE 0.21% vs 0.89% (p=0.034), and mortality 1.28% vs 3.20% (p=0.003). After open lung resection, prophylaxis was associated with lower PE and mortality but higher bleeding and healthcare use. After minimally invasive lung resection, thromboembolic outcomes did not significantly differ, while bleeding and healthcare use were higher. Enoxaparin accounted for 79.35% of prophylaxis prescriptions; thromboembolic outcomes did not significantly differ between apixaban and enoxaparin. Conclusions: Associations between post-discharge thromboprophylaxis and outcomes differed across thoracic procedures and operative approaches. Favorable associations after esophagectomy contrasted with less consistent lung resection findings, supporting prospective studies to define procedure- and risk-specific prophylaxis strategies.

The authors' abstract, as published at the source. Journal of the American College of Surgeons, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Internal Medicine

Internal MedicineMedicine